HM15912, a Novel Long-Acting Glucagon-Like Peptide-2 Analog, Improves Intestinal Growth and Absorption Capacity in a Male Rat Model of Short Bowel Syndrome

短肠综合征 胰高血糖素样肽-2 医学 加药 内科学 内分泌学 药理学 胃肠病学 肽 生物 肠外营养 生物化学
作者
Jaehyuk Choi,Jinbong Lee,Eunjin Park,Hyunjoo Kwon,Daejin Kim,Sungmin Bae,In Young Choi,Ha Hyung Kim
出处
期刊:Journal of Pharmacology and Experimental Therapeutics [American Society for Pharmacology and Experimental Therapeutics]
卷期号:384 (2): 277-286 被引量:6
标识
DOI:10.1124/jpet.122.001381
摘要

Extensive bowel resection caused by various diseases that affect the intestines, such as Crohn's disease, volvulus, and cancer, leads to short bowel syndrome (SBS). Teduglutide is the only approved glucagon-like peptide-2 (GLP-2) drug for SBS; however, it requires daily administration. A novel GLP-2 analog with a prolonged duration of action to reduce dosing frequency and promote a greater efficacy may provide patients with a better quality of life. In the present study, the sustained exposure of HM15912 was characterized in normal male rats. The efficacy of HM15912 on intestinal growth and absorption capacity was also evaluated in normal male mice, rats, and SBS rats. HM15912 exhibited a remarkably extended half-life (42.3 hours) compared with teduglutide (0.6 hours) in rats. Despite somewhat lower in vitro potency on GLP-2 receptor than human GLP-2 or teduglutide, this longer-lasting mode of action promotes HM15912 to be more effective in terms of small intestinal growth than existing GLP-2 analogs even with a less frequent dosing interval of as little as once a week in rodents, including SBS rats. Furthermore, the small intestinal weight was approximately doubled, and the D-xylose absorption was significantly increased after pre-treatment of existing GLP-2 analogs on the market or under clinical development followed by HM15912 in rodents. These results indicate that HM15912 possesses a significant small bowel trophic effect driven by continuously increased exposure, supporting that HM15912 may be a novel treatment option with greater efficacy and the longest dosing interval among existing GLP-2 analogs for SBS with intestinal failure. SIGNIFICANCE STATEMENT: HM15912, a novel long-acting glucagon-like peptide-2 (GLP-2) analog, has a significant small bowel hypertrophic effect in rodents with a reduced frequency of administration compared to the existing GLP-2 analogs on the market or currently under clinical development. This study supports the possibility that HM15912 could be administered much less frequently than other long-acting GLP-2 analogs for patients with short bowel syndrome.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
rumengzhuo完成签到,获得积分10
1秒前
小锤发布了新的文献求助10
1秒前
斯文可仁完成签到,获得积分10
1秒前
1秒前
2秒前
2秒前
ZD发布了新的文献求助10
2秒前
李刚发布了新的文献求助10
2秒前
烂漫的金针菇完成签到,获得积分10
3秒前
Orange的应助被Drcai采纳,获得10
3秒前
nfnf发布了新的文献求助10
4秒前
波纹疾走打字机完成签到,获得积分20
4秒前
lilili的应助被zbw采纳,获得10
4秒前
4秒前
ding的应助被zuo采纳,获得10
4秒前
5秒前
5秒前
李小涛完成签到 ,获得积分10
5秒前
6秒前
6秒前
nihao发布了新的文献求助10
6秒前
张鑫发布了新的文献求助10
6秒前
落寞语兰发布了新的文献求助10
6秒前
小朱雀完成签到,获得积分10
7秒前
火火完成签到,获得积分10
7秒前
微血管发布了新的文献求助10
7秒前
yyy发布了新的文献求助10
7秒前
我是老大的应助被阿萍采纳,获得10
8秒前
追寻定帮发布了新的文献求助10
8秒前
9秒前
FashionBoy的应助被yanyh采纳,获得10
9秒前
彭于晏的应助被玉林采纳,获得10
10秒前
qianzhihe发布了新的文献求助10
10秒前
daomaihu发布了新的文献求助100
10秒前
10秒前
在水一方的应助被惠1采纳,获得10
11秒前
科研小趴菜完成签到 ,获得积分10
11秒前
zbw发布了新的文献求助10
11秒前
桑霁阳完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187748
求助须知:如何正确求助?哪些是违规求助? 9575825
关于积分的说明 21843288
捐赠科研通 7785628
什么是DOI,文献DOI怎么找? 3435097
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2482000